Results of the Phase II GAGE Trial in CLL
Joseph M. Flynn, DO, MPH, co-director, Division of Hematology; co-director, LIVESTRONG Survivorship Center of Excellence; medical director, James Survivorship Clinics, The Ohio State University, James Cancer Hospital, discusses the results of the phase II GAGE study, which compared 1000 mg vs 2000 mg of obinutuzumab in patients with chronic lymphocytic leukemia (CLL).
Joseph M. Flynn, DO, MPH, co-director, Division of Hematology; co-director, LIVESTRONG Survivorship Center of Excellence; medical director, James Survivorship Clinics, The Ohio State University, James Cancer Hospital, discusses the results of the phase II GAGE study, which compared 1000 mg vs 2000 mg of obinutuzumab in patients with chronic lymphocytic leukemia (CLL).
Clinical Pearls:
- Obinutuzumab is a type II, anti-CD20 monoclonal antibody.
- Earlier trials examining obinutuzumab in CLL demonstrated single-agent activity with suggestion of a dose response.​
- In this phase II multicenter study, 80 patients were randomized to receive either 1000 mg or 2000 mg of obinutuzumab.
- Results showed the overall response rate (ORR) was 67% in the 2000mg arm vs 49% in the 1000 mg arm. However, this data was not statistically significant.
- The safety profile was consistent with other monoclonal antibodies.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More
